Chia Tai Tianqing's TQB2210 Approved for Advanced Malignant Tumor Study
CompanyDrug

Chia Tai Tianqing’s TQB2210 Approved for Advanced Malignant Tumor Study

CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access
CompanyDeals

CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access

Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline
Company

Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline

Jiangsu Hengrui Pharmaceuticals Inks Global License Deal with Merck for HRS-5346
CompanyDeals

Jiangsu Hengrui Pharmaceuticals Inks Global License Deal with Merck for HRS-5346

Sichuan Kelun-Biotech Gains NMPA Approval for SKB107 Bone Metastasis Trial
CompanyDrug

Sichuan Kelun-Biotech Gains NMPA Approval for SKB107 Bone Metastasis Trial

Abbisko Therapeutics Receives NMPA Approval for ACH Drug ABSK061
CompanyDrug

Abbisko Therapeutics Receives NMPA Approval for ACH Drug ABSK061

Fapon Biotech Partners with Sansure to Develop Next-Generation Diagnostic Solutions
CompanyDeals

Fapon Biotech Partners with Sansure to Develop Next-Generation Diagnostic Solutions

AstraZeneca Officially Launches Fasenra for Severe Eosinophilic Asthma in China
CompanyDrug

AstraZeneca Officially Launches Fasenra for Severe Eosinophilic Asthma in China

United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug
CompanyDeals

United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug

Fapon Biotech Partners with Tencent Healthcare to Boost IVD and Medical Device Fields
CompanyDeals

Fapon Biotech Partners with Tencent Healthcare to Boost IVD and Medical Device Fields

Joint Biosciences' OVV-01 Receives FDA Fast Track Designation for Soft Tissue Sarcoma Trial
CompanyDrug

Joint Biosciences’ OVV-01 Receives FDA Fast Track Designation for Soft Tissue Sarcoma Trial

Sino Biopharmaceutical's Culmerciclib Shows Positive Results in Phase III Breast Cancer Trial
CompanyDrug

Sino Biopharmaceutical’s Culmerciclib Shows Positive Results in Phase III Breast Cancer Trial